Abstract
Tuberculosis (TB) remains as one of the most serious public health problems worldwide. It is one of the main causes of death in poor and developing countries, especially in sub-Saharan Africa, where it may be associated with the human immunodeficiency virus (HIV). It has been estimated that one third of the world population is infected by Mycobacterium tuberculosis (Mtb), and there were about 8.7 million new TB cases, and about 1.4 million yearly deaths due to TB in 2011. DOTS is the currently used drug therapy in TB but there is non-compliance which results in emergence of resistance. Bacille Calmette Guérin (BCG), an attenuated vaccine derived from Mycobacterium bovis, is the only licensed TB vaccine, but not recommended in HIV-infected infants. There are 14 vaccine candidates that have entered clinical trials and over 35 candidates in discovery and preclinical development. Mycobacterium indicus pranii [Mw; MIP] and M. vaccae are in phase III clinical trial and the Drug Controller of India licensed MIP for human use in India.
Keywords: Clinical trials, review, tuberculosis, tuberculosis vaccines.
Infectious Disorders - Drug Targets
Title:Tuberculosis Vaccines: Hopes and Hurdles
Volume: 13 Issue: 5
Author(s): Mohamed J. Ahsan, Shiv K. Garg, Bharat Vashistha and Piush Sharma
Affiliation:
Keywords: Clinical trials, review, tuberculosis, tuberculosis vaccines.
Abstract: Tuberculosis (TB) remains as one of the most serious public health problems worldwide. It is one of the main causes of death in poor and developing countries, especially in sub-Saharan Africa, where it may be associated with the human immunodeficiency virus (HIV). It has been estimated that one third of the world population is infected by Mycobacterium tuberculosis (Mtb), and there were about 8.7 million new TB cases, and about 1.4 million yearly deaths due to TB in 2011. DOTS is the currently used drug therapy in TB but there is non-compliance which results in emergence of resistance. Bacille Calmette Guérin (BCG), an attenuated vaccine derived from Mycobacterium bovis, is the only licensed TB vaccine, but not recommended in HIV-infected infants. There are 14 vaccine candidates that have entered clinical trials and over 35 candidates in discovery and preclinical development. Mycobacterium indicus pranii [Mw; MIP] and M. vaccae are in phase III clinical trial and the Drug Controller of India licensed MIP for human use in India.
Export Options
About this article
Cite this article as:
Ahsan J. Mohamed, Garg K. Shiv, Vashistha Bharat and Sharma Piush, Tuberculosis Vaccines: Hopes and Hurdles, Infectious Disorders - Drug Targets 2013; 13 (5) . https://dx.doi.org/10.2174/1871526513666131201125513
DOI https://dx.doi.org/10.2174/1871526513666131201125513 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Docking Study for Analyzing the Inhibitory Effect of Anti-inflammatory Plant Compound Against Tumour Necrosis Factor (TNF-α)
Current Drug Therapy Visceral Leishmaniasis: Advances in Treatment
Recent Patents on Anti-Infective Drug Discovery Synthesis and SAR Evaluation of Mercapto Triazolobenzothiazole Derivatives as Anti-tuberculosis Agents
Anti-Infective Agents Nanomedicines as Drug Delivery Carriers of Anti-Tubercular Drugs: From Pathogenesis to Infection Control
Current Drug Delivery A Perspective on Monoamine Oxidase Enzyme as Drug Target: Challenges and Opportunities
Current Drug Targets Recent Advances in Azo Dye Degrading Enzyme Research
Current Protein & Peptide Science Exploring and Exploiting Biologically Relevant Chemical Space
Current Drug Targets Recent Advances for Cell / Gene Therapy in Rheumatoid Arthritis
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Infection, Infectious Agents and Vascular Disease
Reviews on Recent Clinical Trials Cancer Immunotherapy: Battling Tumors with Gene Vaccines
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Effective Therapy with the Neuroleptic Thioridazine as an Adjunct to Second Line of Defence Drugs, and the Potential that Thioridazine Offers for New Patents that Cover a Variety of “New Uses”
Recent Patents on Anti-Infective Drug Discovery Nanoformulations of Moxifloxacin, Econozole and Ethionamide as Novel Treatment Regimens Against MDR TB - An Experimental Study
Current Nanoscience TB Diagnostics – Old and New
Current Respiratory Medicine Reviews Control by Substrate of the Cytochrome P450-Dependent Redox Machinery: Mechanistic Insights
Current Drug Metabolism Surfactant Therapy of Pulmonary Conditions Excluding those with Primary Surfactant Deficiency and Bronchoscopy as Delivery Method: An Overview of Russian Patents and Publications
Recent Patents on Drug Delivery & Formulation Bactericidal Activity of Usnic Acid-Loaded Electrospun Fibers
Recent Patents on Nanotechnology Nanoparticle-Based Diagnosis and Therapy
Current Drug Targets Graphical Abstracts:
Current Organic Chemistry A Review on Coumarin Derivatives as Potent Anti-tuberculosis Agents
Mini-Reviews in Medicinal Chemistry Type II NADH:Menaquinone Oxidoreductase of Mycobacterium tuberculosis
Infectious Disorders - Drug Targets